Literature DB >> 1906264

Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.

J A Bosso1, B A Saxon, J M Matsen.   

Abstract

The comparative in vitro activity and synergy of cefepime were evaluated with clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. The activity of cefepime, both alone and in combination, was comparable to those of other antibiotics. The clinical efficacy of cefepime in cystic fibrosis patients merits investigation.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1906264      PMCID： PMC245101          DOI： 10.1128/AAC.35.4.783

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

2.  Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.

Authors:  U B Schaad; J Wedgwood-Krucko; K Guenin; U Buehlmann; R Kraemer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

3.  Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.

Authors:  N J Khan; J A Bihl; R F Schell; J L LeFrock; S J Weber
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

4.  Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.

Authors:  J Fung-Tomc; E Huczko; M Pearce; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.

Authors:  J Fung-Tomc; T J Dougherty; F J DeOrio; V Simich-Jacobson; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

6.  Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis.

Authors:  R Padoan; A Brienza; R M Crossignani; G Lodi; A Giunta; B M Assael; F Granata; E Passarella; P A Vallaperta; L Xerri
Journal:  J Pediatr       Date:  1983-08       Impact factor: 4.406

7.  Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis.

Authors:  R Gold; A Overmeyer; B Knie; P C Fleming; H Levison
Journal:  Pediatr Infect Dis       Date:  1985 Mar-Apr

8.  Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.

Authors:  R E Kessler; M Bies; R E Buck; D R Chisholm; T A Pursiano; Y H Tsai; M Misiek; K E Price; F Leitner
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

9.  Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.

Authors:  J A Bosso; P G Black
Journal:  Pediatr Infect Dis J       Date:  1988-03       Impact factor: 2.129
  9 in total
  7 in total

1.  Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  Vanthida Huang; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Pharmacokinetics of cefepime in cystic fibrosis patients.

Authors:  C E Huls; R A Prince; D K Seilheimer; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

3.  Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.

Authors:  G Manno; E Ugolotti; M L Belli; M L Fenu; L Romano; M Cruciani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-01-25       Impact factor: 3.267

Review 4.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

5.  Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.

Authors:  P D Lister; W E Sanders; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

Review 6.  Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment.

Authors:  Luiz Vicente Ribeiro Ferreira da Silva Filho; Flavia de Aguiar Ferreira; Francisco José Caldeira Reis; Murilo Carlos Amorim de Britto; Carlos Emilio Levy; Otavio Clark; José Dirceu Ribeiro
Journal:  J Bras Pneumol       Date:  2013 Jun-Aug       Impact factor: 2.624

Review 7.  Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches.

Authors:  Viola C Scoffone; Laurent R Chiarelli; Gabriele Trespidi; Massimo Mentasti; Giovanna Riccardi; Silvia Buroni
Journal:  Front Microbiol       Date:  2017-08-22       Impact factor: 5.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.